SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-013471
Filing Date
2023-04-19
Accepted
2023-04-19 16:06:14
Documents
13
Period of Report
2023-04-13
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fate-20230413.htm   iXBRL 8-K 55908
2 EX-3.1 fate-ex3_1.htm EX-3 17060
  Complete submission text file 0000950170-23-013471.txt   192367

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fate-20230413_pre.xml EX-101.PRE 9856
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fate-20230413_lab.xml EX-101.LAB 13351
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fate-20230413.xsd EX-101.SCH 2493
7 EXTRACTED XBRL INSTANCE DOCUMENT fate-20230413_htm.xml XML 4701
Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

IRS No.: 651311552 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36076 | Film No.: 23830097
SIC: 2836 Biological Products, (No Diagnostic Substances)